Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina
Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina
复制标题
DOI：
10.1016/j.cccn.2004.09.026
复制
发表时间：
2005-02-01
影响因子：
5
通讯作者：
Gao, RL
中科院分区：
文献类型：
--
作者：
Li, JJ;Hu, SS;Gao, RL
背景：他汀类药物可以降低胆固醇和炎症。血脂康是一种从中国红曲中提取的胆固醇提取物，能有效地调节血脂。然而，关于血脂康对稳定型心绞痛患者血浆C反应蛋白（CRP）和血脂谱的快速影响的信息有限。我们评估了血脂谱和CRP的短期时间过程中的影响，血脂康在稳定型心绞痛patients with stable angina.Methods：48例稳定型心绞痛患者被随机分配到1200或2400毫克/天的血脂康。所有患者于第0、1、7、14天抽血检测血脂和CRP水平，并于第0、14天检测肝酶。结果：两种剂量的血脂康均能显著降低第1天的CRP中位数和平均水平（1200 mg/天组为13.0%，2400 mg/天组为16.6%; 1200 mg/天组为14.7%，2400 mg/天组为18.4%）和第7天（1200 mg/天组18.3%，2400 mg/天组20.2%; 1200 mg/天组18.5%，2400 mg/天组22.6%）以及第14天（1200 mg/天组为28.6%，2400 mg/天组为30.4%; 1200 mg/天组为21.7%，2400 mg/天组为24.8%）与基线相比，无剂量依赖性效应，但具有时间依赖性。此外，在第1天和第7天未发现血脂谱变化。然而，与第14天的基线相比，两种剂量的血脂康均导致总胆固醇（TC，13%和22%）和低密度脂蛋白（LDL）胆固醇（23%和32%）显着降低。血脂康2400 mg/d组较1200 mg/d组降低TC和LDL胆固醇的作用更明显（p
Background: Reduction of cholesterol and inflammation can be achieved by administration of a statin. Xuezhikang, an extract of cholestin, available from Chinese red yeast rice, could effectively modify the lipid profile. However, limited information is available regarding rapid effects of Xuezhikang on plasma C-reactive protein (CRP) and the lipid profile in patients with stable angina. We evaluated the short-term time course effects of lipid profile and CRP by Xuezhikang in patients with stable angina.Methods: Forty-eight consecutive patients with stable angina were randomly assigned to 1200 or 2400 mg/day of Xuezhikang. Blood samples were drawn at days 0, 1, 7 and 14 for lipid profile and CRP levels in all patients, and hepatic enzymes were also evaluated at days 0 and 14.Results: Both doses of Xuezhikang induced significant reductions in median CRP levels and in mean CRP levels at day 1 (13.0% with 1200 and 16.6% with 2400 mg/day; 14.7% with 1200 and 18.4% with 2400 mg/day), and at day 7 (18.3% with 1200 and 20.2% with 2400 mg/day; 18.5% with 1200 and 22.6% with 2400 mg/day) as well as at day 14 (28.6% with 1200 and 30.4% with 2400 mg/day; 21.7% with 1200 and 24.8% with 2400 mg/day) compared with baseline without a dose-dependent effect but a time-dependent manner. In addition, no changes were found at days I and 7 regarding lipid profile. However, both doses of Xuezhikang induced significant reductions in total cholesterol (TC, 13% and 22%), and low-density lipoprotein (LDL) cholesterol (23% and 32%) compared with baseline at day 14. The higher dose of Xuezhikang (2400 mg/day) resulted in significantly greater reductions in TC and LDL cholesterol compared with 1200 mg/day group (p